Residency · New York, NY
Sponsored by Icahn School of Medicine at Mount Sinai
Atopic dermatitis.
Lancet (London, England) · 2025 · 233 citations · Emma Guttman, Patrick Brunner
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
Journal of the American Academy of Dermatology · 2021 · 620 citations · Lindy Fox
Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics.
Nature reviews. Genetics · 2021 · 781 citations · Andrew Ji
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
The British journal of dermatology · 2021 · 502 citations · Emma Guttman, Leon Kircik
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
The New England journal of medicine · 2023 · 275 citations · Emma Guttman
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet (London, England) · 2021 · 463 citations · Emma Guttman
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper.
Allergy · 2023 · 222 citations · Emma Guttman
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Journal of the American Academy of Dermatology · 2023 · 241 citations · Leon Kircik